

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/09797

|  |   |  |
|--|---|--|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC: A61K 35/00 (2006.01); A61K 38/00 (2006.01); C07K 14/00 (2006.01)<br><br>USPC: 514/1, 2; 530/300<br>According to International Patent Classification (IPC) or to both national classification and IPC  |   |  |
| <b>B. FIELDS SEARCHED</b><br><br>Minimum documentation searched (classification system followed by classification symbols)<br>U.S.: 514/1, 2; 530/300<br><br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br><br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)   |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>  |   |  |
| Category *<br>x<br>y<br>y<br>y   | Citation of document, with indication, where appropriate, of the relevant passages<br>US 6,423,705 (TRACEY et al) 17 January 2002 (17.01/2002), Abstract, col 3, col 8.<br><br>KIM Y.K. et al. Expression of PAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. 2002.J. Endocrinol Metab. 283, E867-E879. see abstract and introduction.<br><br>LEON J. et al. Modulation of rat striatal glutamatergic response in search for new neuroprotective agents: evaluation of melatonin and some lysineurenine derivatives. 2003. Brain Research Bulletin. 45, 525-530. See abstract and intro. | Relevant to claim No.<br>1-2, 5-8<br>3-4<br>3<br>4 |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family member.  |   |  |
| Special categories of cited documents<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"B" earlier applications or patents published on or after the international filing date<br>"L" document which may derive directly or indirectly from the invention or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"X" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention<br>"Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Z" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other cited documents, such combination being obvious to a person skilled in the art<br>"A" document number of the same patent family |   |  |
| Date of the actual completion of the international search<br>31 May 2007 (31.05.2007)  |   |  |
| Name and mailing address of the ISA/US<br>Mail Stop PCT, Attn: ISA/US<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, Virginia 22313-1450<br>Facsimile No. (571) 273-3201  |   |  |
| Date of mailing of the international search report<br>20 JUN 2007<br>Authorized officer<br>Steven H. Standley<br>Telephone No. (571) 272-7900  |   |  |

Form PCT/ISA/210 (second sheet) (April 2005)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US05/09797

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| x          | SHENG R. EDT, A tetrahydroacridine dervative inhibits cerebral ischemia and protects rat cortical neurons against glutamate-induced cytotoxicity. 2002. Acta Pharmacologica Sinica. 24, 390-393. see title. | 9                     |

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
WO 2005/092068 A3

(51) International Patent Classification:

A61K 35/00 (2006.01) C07K 14/00 (2006.01)  
A61K 38/00 (2006.01)

Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 (US).

(21) International Application Number:

PCT/US2005/009797

(74) Agent: WILSON, Whitney, N.; Covington & Burling, 1201 Pennsylvania Avenue, N.W., Washington, DC 20004-2401 (US).

(22) International Filing Date: 23 March 2005 (23.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/556,000 24 March 2004 (24.03.2004) US

(71) Applicants (for all designated States except US): FAS-GEN, LLC [US/US]; The Factory Building, 2400 Boston Street, Baltimore, MD 21224 (US). JOHNS HOPKINS UNIVERSITY [US/US]; 4910 Eastern Avenue, Baltimore, MD 21224 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MCCULLOUGH, Louise, D. [US/US]; Department of Neuroscience, 1006B Preclinical Teaching Building, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 (US). LI, Hong [US/US]; Department of Neuroscience, 1006B Preclinical Teaching Building, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 (US). MCFADDEN, Jill [US/US]; Department of Neuroscience, 1006B Preclinical Teaching Building, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 (US). RONNETT, Gabriele, V. [US/US]; Department of Neuroscience, 1006B Preclinical Teaching Building,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the International search report:

20 September 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL METHOD OF NEUROPROTECTION BY PHARMACOLOGICAL INHIBITION OF AMP-ACTIVATED PROTEIN KINASE

(57) Abstract: A method of neuroprotection which comprises administration of an AMPK inhibitor to a patient who is experiencing or has experienced a stroke, the compound being an AMPK inhibitor. Treatments with these agents significantly reduce the size of infarcts, and therefore minimize the loss of brain tissue and neurons. Thus, function can be preserved after stroke or ischemic injury in the brain. Similarly, neuronal loss can be minimized in degenerative diseases that cause neuronal compromise by perturbing energy utilization and availability in neurons.